Insulin degludec — new possibilities and solutions in Diabetes Mellitus patients treatment

Abstract

Insulin is most effective treatment for compensation of Diabetes Mellitus. Long-acting insulin analogues glargine and detemir in comparison with NPH provide better  glycaemic control in Diabetes Mellitus with lower risk of hypoglycaemia. However, the fear of hypoglycaemia and complexity of insulin treatment persist the main  barriers of insulin’ initiation and intensification still now. Insulin degludec (Tresiba) is new generation of insulin analogues with ultra-long duration of action.  Innovative mechanism of prolongation of insulin action ensures the duration of its hypoglycaemic action for more than 42 hours with minimum variability during  twenty-four hours. Constant profile of insulin degludec action provides lower risk of hypoglycaemia in comparison with insulin glargine and  allows the patient to  follow flexible insulin injections regimen; this increases the compliance of the patient to the treatment. Thereby the use of insulin degludec in routine clinical practice  provides an advantage in  the treatment of Diabetes Mellitus.